North America Molecular Diagnostics Market | Growth, Trends, and Forecast (2020

ABOUT THIS REPORT
- Market Snapshot
- Market Overview
- Scope of the report
- Key Market Trends
- Competitive Landscape
- Major Players
TABLE OF CONTENTS

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

CAGR:

9 %

Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Molecular diagnostics is considered to be the best method to identify and characterize a microorganism. The market is mainly driven by increasing demand for point-of-care diagnostics, recent advancements in pharmacogenomics and large outbreaks of bacterial and viral epidemics. The molecular diagnostics test must be precise, rapid, and also be able to measure the infectious burden. Better testing quickly identifies the organism’s strain and drug susceptibility, thus, reducing the delay in finding the right antibiotic. Molecular diagnostics has played a vital role in changing the face of disease diagnostics and assuring speedy detection and accurate care for critically ill patients. The increase in the number of infectious diseases and cancer cases in the United States have led to a shift in trend from the traditional diagnostic methods to molecular diagnostics. The identification of these diseases at an early stage has become easy using molecular tests, coupled with pharmacogenomics, which is expected to fuel the market growth.

Scope of the report

Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, insertions, and others), which may or may not be associated with diseases.

Technology
		In Situ Hybridization
		Chips and Microarrays
		Mass Spectrometry (MS)
		Sequencing
		PCR
		Other Technologies

Application
		Infectious Disease
		Oncology
		Pharmacogenomics
		Microbiology
		Genetic Disease Screening
		Human Leukocyte Antigen Typing
		Blood Screening

Product
		Instrument
		Reagent
		Other Products

End User
		Hospitals
		Laboratories
		Other End Users

Geography

North America
	United States
	Canada
	Mexico

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oncology Segment is Expected to Show Better Growth in the Forecast Years

Based on Application, the market is segmented into infectious disease, oncology, pharmacogenomics, microbiology, genetic disease screening, human leukocyte antigen typing and blood screening. Oncology deals with the diagnosis and treatment of tumors and cancers. The high growth of the segment is attributed to rising burden of various types of cancer. Cancer is one of the leading causes of morbidity and mortality. According to the American Cancer Society, in the United States 1,762,450 new cancer cases and 606,880 cancer deaths were estimated for 2019 alone. Thus, with the increasing burden of cancer and rising awareness among people for early detection of cancer is estimated to enhance the usage of molecular diagnostic in the forecast period.

To understand key trends, Download Sample Report

Competitive Landscape

The international players in the market studied include Abbott Laboratories, Agilent Technologies, Becton, Dickinson And Company, Danaher Corporation (Cepheid Inc), EXACT Sciences Corporation, F. Hoffmann-la Roche Ltd, Hologic Corporation, Illumina, Inc, Myriad Genetics, Inc, and Qiagen. The market is moderately competitive and major share of the market is grabbed by the global companies as North America is one of the most developed region for such companies.

Major Players

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Increasing Demand for Point-of-care Diagnostics
  2. 4.2.2 Recent Advancements in Pharmacogenomics
  3. 4.2.3 Large Outbreaks of Bacterial And Viral Epidemics
3. 4.3 Market Restraints
  1. 4.3.1 Stringent Regulatory Framework
4. 4.4 Porter's Five Forces Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 Technology
  1. 5.1.1 In Situ Hybridization
  2. 5.1.2 Chips and Microarrays
  3. 5.1.3 Mass Spectrometry (MS)
  4. 5.1.4 Sequencing
  5. 5.1.5 PCR
  6. 5.1.6 Other Technologies
2. 5.2 Application
  1. 5.2.1 Infectious Disease
  2. 5.2.2 Oncology
  3. 5.2.3 Pharmacogenomics
  4. 5.2.4 Microbiology
  5. 5.2.5 Genetic Disease Screening
  6. 5.2.6 Human Leukocyte Antigen Typing
  7. 5.2.7 Blood Screening
3. 5.3 Product
  1. 5.3.1 Instrument
  2. 5.3.2 Reagent
  3. 5.3.3 Other Products
4. 5.4 End User
  1. 5.4.1 Hospitals
  2. 5.4.2 Laboratories
  3. 5.4.3 Other End Users
5. 5.5 Geography
  1. 5.5.1 North America
    1. 5.5.1.1 United States
    2. 5.5.1.2 Canada
    3. 5.5.1.3 Mexico
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Abbott Laboratories
  2. 6.1.2 Agilent Technologies
  3. 6.1.3 Becton, Dickinson And Company
  4. 6.1.4 Danaher Corporation (Cepheid Inc)
  5. 6.1.5 EXACT Sciences Corporation
  6. 6.1.6 F. Hoffmann-la Roche Ltd
  7. 6.1.7 Hologic Corporation
  8. 6.1.8 Illumina, Inc.
  9. 6.1.9 Myriad Genetics, Inc.
  10. 6.1.10 Qiagen
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments